Document:

Exhibit 10.39

 

QUEST PATENT RESEARCH CORPORATION

 

2017 EQUITY INCENTIVE PLAN

 

Restricted Stock Agreement

 

This Restricted Stock Award Agreement evidences
a grant of Restricted Stock pursuant to the provisions of the 2017 Equity Incentive Plan, as amended (the “Plan”) of
Quest Patent Research Corporation, a Delaware corporation (the “Company”) to the individual whose name appears below
(the “Participant”), pursuant to the provisions of the Plan and on the following terms and conditions (capitalized
terms not otherwise defined herein shall have the meaning ascribed thereto in the Plan):

 

1. Name of Participant:

 

 2. Number of Shares of Restricted Stock (the “Shares”):

 

3. Date of Grant:

 

4. Issuance of the Shares:
The Shares shall be restricted securities, as defined in Rule 144, of the Securities and Exchange Commission (the “SEC”)
pursuant to the Securities Act of 1933, as amended (the “Securities Act”). The right to the Shares vest in full immediately.

 

5. Withholding Tax:
If required under applicable law, the Participant shall pay or make arrangements for payment of any withholding tax required to be paid
or withheld with respect to the Shares.

 

6. Accredited Investor:
The Participant acknowledges that he is familiar with the definition of accredited investor, as defined in Rule 502 of the SEC pursuant
to the Securities Act, that he is an accredited investor and that he has accurately completed the accredited investor questionnaire set
forth as Exhibit A to this Restricted Stock Agreement.

 

7. Governing Law: This
Agreement shall be governed by the laws of the State of Delaware applicable to agreements executed and to be performed wholly within such
state without regard to principles of conflict of laws.

 

The Participant hereby acknowledges receipt of a copy of the Plan as
presently in effect. The text and all of the terms and provisions of the Plan are incorporated herein by reference, and the grant of the
Shares is subject to these terms and provisions in all respects.

 

[Signatures on following page]

 

     

    

    

 

QUEST PATENT RESEARCH CORPORATION

 

	By:		 
	Name:	Jon C. Scahill	 
	 	 	 
	Title:	Chief Executive Officer	 
	 	 	 
	Agreed to and Accepted as of________________:	 

 

	 	 
	 	 	 
	Participant	 

 

    2

    

    

 

Exhibit A To Restricted Stock Agreement

 

Accredited Investor Questionnaire

 

The following are tests for an individual accredited
investor. Please initial which tests are applicable. Please initial all that apply.

 

_____ A natural person whose individual net worth
or joint net worth with Subscriber’s spouse, at the time of this purchase exceeds $1,000,000 (PLEASE NOTE: In calculating net worth,
you include all of your assets (other than your primary residence), whether liquid or illiquid, such as cash, stock, securities, personal
property and real estate based on the fair market value of such property MINUS all debts and liabilities (other than indebtedness secured
by your primary residence, up to the estimated fair market value of the primary residence, unless the borrowing occurs in the 60 days
preceding the purchase of the Units and is not in connection with the acquisition of the primary residence. In such cases, the debt secured
by the primary residence must be treated as a liability in the net worth calculation.). In the event any incremental mortgage or other
indebtedness secured by your primary residence occurs in the 60 days preceding the date of the purchase of the Units, the incremental
borrowing must be treated as a liability and deducted from your net worth even though the value of your primary residence will not be
included as an asset. Further, the amount of any mortgage or other indebtedness secured by your primary residence that exceeds the fair
market value of the residence should also be deducted from your net worth);

 

___ A natural person who had an individual income
in excess of $200,000 in each of the two most recent years or joint income with Subscriber’s spouse in excess of $300,000 in each
of those years and has a reasonable expectation of reaching the same income level in the current year;

 

___ A director or executive officer of the Company.

 

 

3Exhibit 10.40

 

INSTRUMENT OF GRANT OF NONQUALIFIED STOCK
OPTION

 

Instrument of Grant issued as of this 22nd
day of February, 2021, from Quest Patent Research Corporation, a Delaware corporation with offices at 411 Theodore Fremd Ave., Suite 206S,
Rye, NY 10580 (hereinafter referred to as “Company”), to ______________, an individual, with her residence at __________________________________________
(hereinafter referred to as the “Option Holder”).

 

W I T 
N E S S E T H:

 

WHEREAS, the Company has, on the date of this Instrument
of Grant, granted Option Holder a nonqualified stock option (the “Option”) to purchase from the Company shares of the Company’s
common stock, par value $0.00003 per share (“Common Stock”), pursuant to the Company’s 2017 Equity Incentive Plan (the
“Plan”); and

 

WHEREFORE, the Company does hereby grant to the
Option Holder the following Option:

 

1. Stock
Option. Subject to the terms and conditions set forth in this Instrument of Grant, the Company hereby grants to the Option Holder
a non-qualified stock option (the “Option”) to purchase from the Company 30,000,000 shares (the “Shares”) of Common
Stock at an exercise price (the “Exercise Price”) set forth in Section 2 of this Instrument of Grant, being not less than
the fair value per share of Common Stock on the date of grant.

 

2. Exercise
Period and Exercise Price.

 

(a) Subject
to Section 2(b), the Option shall be exercisable will become exercisable cumulatively as follows:

 

(i) The Option shall become exercisable as to 10,000,000
Option Shares at an Exercise Price of $0.01 per share upon the commencement of trading of the Common Stock on the OTCQB;

 

(ii) The Option shall become exercisable as to
10,000,000 Option Shares, at an Exercise Price of $0.03 per share, on first date on which the Company files with the SEC a Form 10-K or
Form 10-Q in which the Company reports stockholders’ equity of at least $5,000,000, and

 

(iii) The Option shall become exercisable as to
10,000,000 Option Shares, at an Exercise Price of $0.05 per share, on the date the trading of the Common Stock commences on a market maintained
by the New York Stock Exchange or the Nasdaq Stock Market.

 

(b) In the
event of the Option Holder’s death or a termination of the Option Holder’s consultancy relationship as a result of a disability,
as defined in the Consulting Agreement dated February 22, 2021 between the Company and the Option Holder (the “Consulting Agreement”),
the Option may be exercised, to the extent it is exercisable on the date of death or termination as a result of a disability, until the
earlier of (x) six month from the date of death or the date or termination of the Option Holder’s consultancy relationship as a
result of a disability or (y) the Expiration Date.

 

(c) In the
event of a termination of the Option Holder’s consultancy with the Company for cause, as defined in Consulting Agreement, prior
to the Expiration Date, the Option shall terminate immediately upon such termination of the Option Holder’s consultancy or termination
of the Consulting Agreement, and the Option Holder shall have no rights under this Agreement from and after the date of termination.

 

     

     

    

 

3. Termination.
The Option shall terminate, and Option Holder shall have no further rights under the Option, on February 21, 2031 (the “Expiration
Date”), subject to earlier termination to the extent provided in Section 2(b) of this Instrument of Grant and subject to the provisions
of the Plan.

 

4. Manner
of Exercise.

 

(a) The
Option shall be exercised by written notice of exercise in the form of Exhibit A to this Instrument of Grant addressed to the Company
and signed by the Option Holder and delivered to the Company along with this Instrument of Grant and payment in full of the Exercise Price
of the Optioned Shares as to which the Option is being exercised. If the Option is exercised in part only, the Company will either issue
a new Instrument of Grant with respect to the unexercised portion of the Option or shall make a notation on this Instrument of Grant reflecting
the partial exercise. The Exercise Price is payable by certified or official bank check or by personal check; provided, however, that
no Optioned Shares shall be issued to Option Holder until the Company has been advised by its bank that the check has cleared.

 

(b) The
Option may also be exercised by the delivery to the Company of shares of Common Stock having a fair market value as of the date of exercise,
equal to the Exercise Price of the Optioned Shares to the extent that the Option is being exercised by written notice of exercise in the
form of Exhibit B to this Instrument of Grant addressed to the Company and signed by the Option Holder. The market value of the Common
Stock shall be determined as follows:

 

(i) If the Common Stock is listed on a national
securities exchange or is quoted on the OTCQX, OTCQB, or OTC Pink or other service which provides information as to the last sale price,
the current value shall be the reported last sale prices of one share of Common Stock on such exchange, market or system on the trading
day prior to the date of exercise of the Option, or if, on any of such dates, no such sale is made on such day, the last reported sale
on such exchange, market or system shall be used; or

 

(ii) If the Common Stock is not so listed or admitted
to unlisted trading privileges or traded, the current value shall be the mean average of the reported last bid and asked prices of one
share of Common Stock as reported by a reporting services selected by the Company, on the last trading day prior to the date of the exercise
of the Option; or

 

(iii) If the Common Stock is not so listed or admitted
to unlisted trading privileges and bid and asked prices are not so reported, the current value of one share of Common Stock shall be an
amount, not less than net tangible book value per share determined in such reasonable manner as may be prescribed by the Compensation
Committee of the Board of Directors of the Company.

 

(c) The
Option by be exercised on a cashless net exercise basis through the issuance of such number of Option Shares as to which the Option is
being exercised as is determined by multiplying the number of Option Shares as to which the Option is being exercised by a fraction, the
numerator of which is the amount by which the market price of the date of exercise exceeds the exercise price and the denominator of which
is the market price on the date of exercise by written notice of exercise in the form of Exhibit C to this Instrument of Grant addressed
to the Company and signed by the Option Holder. The Option shall be deemed exercised as to the number of shares as to which the Option
is being exercised, even though a lesser number of Option Shares are issued. If the Option is being exercised with respect to Options
with different Exercise Prices, a separate calculation shall be made with respect to each Exercise Price.

 

    2 

     

    

 

(d) The
Option may also be exercised through a brokerage transaction in a manner approved by the Compensation Committee.

 

5. Adjustment
Provisions. The number of shares of Common Stock subject to the Option and the Exercise Price shall be adjusted in accordance with
generally accepted accounting principles in the event of a stock dividend, stock split, stock distribution, reverse split or other combination
of shares, recapitalization or otherwise, which affects the Common Stock.

 

6. Not
Transferable. The Option is not transferable by the Option Holder, and may be exercised only by the Option Holder except that, in
the event of the Option Holder’s death or disability, the Option may be exercised by Option Holder’s legal representative
or by the persons to whom the Option is transferred by will or the laws of descent and distribution.

 

7. No
Rights as a Stockholder. The Option Holder shall have no interest in and shall not be entitled to any voting rights or any dividend
or other rights or privileges of a stockholder of the Company with respect to any shares of Common Stock issuable upon exercise of this
Option prior to the exercise of this Option and payment of the Exercise Price of the Optioned Shares.

 

8. No
Rights to Continued Consultancy Relationship or Employment. Nothing in this Instrument of Grant shall be constructed as an employment
or consulting agreement or to grant the Option Holder any rights to continue as an employee of or consultant to the Company.

 

9. Legality.
Anything in this Option to the contrary notwithstanding, the Option Holder agrees that he or she will not exercise the Option, and that
the Company will not be obligated to issue any shares of Common Stock pursuant to this Option, if the exercise of the Option or the issuance
of such shares shall constitute a violation by the Option Holder or by the Company of any provisions of any law or of any regulation of
any governmental authority. Any determination by the Board of Directors or the Compensation Committee of the Board of Directors, if appointed,
as to the applicability of the preceding sentence shall be binding on the Company and the Option Holder. In the event that the Compensation
Committee shall not have been appointed, references to the Compensation Committee shall relate to the Board of Directors. The Company
shall not be obligated to take any affirmative action in order to cause the exercise of the Option or the issuance of shares pursuant
thereto to comply with such law or regulation. In this connection, the Option Holder understands that the Optioned Shares, if and when
issued, will be restricted securities, as defined in Rule 144 of the Securities and Exchange Commission pursuant to the Securities Act
unless issued pursuant to a registration statement on Form S-8. The Company shall not be required to issue any Shares if the Company is
not satisfied that the issuance thereof is permitted pursuant to the Securities Act without registration under the Securities Act.

 

10. Action
by Company. The existence of the Option shall not effect in any way the right or power of the Company or its stockholders to make
or authorize any or all adjustments, recapitalization, reorganizations or other changes in the Company’s capital structure or its
business, or any merger or consolidation of the Company, or any issue of bonds, debentures, preferred or prior preference stocks ahead
of or affecting the Common Stock or the rights thereof, or the dissolution or liquidation of the Company, or any sale or transfer of all
or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.

 

    3 

     

    

 

11. Interpretation.
As a condition of the granting of the Option, the Option Holder and each person who succeeds to the Option Holder’s rights hereunder,
agrees that any dispute or disagreement which shall arise under or as a result of or pursuant to this Option shall be determined by the
Committee in its sole discretion and that any interpretation by the Committee of the terms of this Agreement shall be final, binding and
conclusive. If no Committee is acting, its functions shall be performed by the Board of Directors, and each reference in this Option to
the Committee shall, in that event, be deemed to refer to the Board of Directors. The rights of the Option Holder with respect to the
Option are subject to the Plan and the interpretations of the Plan by the Committee.

 

12. Notice.
Any notice which either party hereto may be required or permitted to give to the other shall be in writing, and any be delivered personally
or by mail, postage prepaid, addressed as follows: to the Company, at 411 Theodore Fremd Ave., Suite 206S, Rye, NY 10580, Attention: Chairman
and Chief Executive Officer, or at such other address as the Company, by notice, may designate in writing from time to time; to the Option
Holder, at the address shown on the records of the Company or at such other address as the Option Holder, by notice to the Company, may
designate in writing from time to time.

 

IN WITNESS WHEREOF, the Company has executed this
Instrument of Grant as of the date first above written.

 

	 	QUEST PATENT RESEARCH CORPORATION.
	 	 	 
	 	By:	
	 	 	Jon Scahill, Chief Executive Officer

 

	 	
    OPTION HOLDER

     

     

    

 

    4 

     

    

 

Exhibit A

 

Date:

 

Quest Patent Research Corporation

411 Theodore Fremd Ave., Suite 206S

Rye, NY 10580

Attention: Chairman and CEO

 

Re: Stock Option Exercise
– Cash Exercise 

 

Gentlemen:

 

I hereby exercise the option to
the extent of _________ shares, and I am tendering with this Notice full payment of the Exercise Price with respect to the Optioned Shares
as to which this Option is being exercised. I further represent and warrant to the Company that I am aware of the tax consequences of
my exercise of the option.

 

	 	Very truly yours,
	 	 
	 	

 

     

     

    

 

Exhibit B

 

Date:

 

Quest Patent Research Corporation

411 Theodore Fremd Ave., Suite 206S

Rye, NY 10580

Attention: Chairman and CEO

 

Re: Stock Option Exercise
– Delivery of Stock 

 

Gentlemen:

 

I hereby exercise the option
to the extent of _________ shares, and I am tendering with this Notice full payment of the Exercise Price in the form of _________
shares of Common Stock having a value, determined as provided in the Instrument of Grant, equal to $ ______, as follows:

 

Total Exercise Price:_________

 

Current Value of Common Stock:________

 

Number of shares of Common Stock
being delivered:___________

 

I further represent and warrant
to the Company that I am aware of the tax consequences of my exercise of the option.

 

	 	Very truly yours,
	 	 
	 	

 

     

     

    

 

Exhibit C

 

Date:

 

Quest Patent Research Corporation

411 Theodore Fremd Ave., Suite 206S

Rye, NY 10580

Attention: Chairman and CEO

 

Re: Stock Option Exercise
– Cashless Net Exercise 

 

Gentlemen:

 

I hereby exercise the option to the extent of _________ shares on a
cashless net exercise basis. The number of shares to be delivered shall be determined as follows:

 

	Number of Shares as to which the Option is exercised:	     	 
	 	 	 
	Exercise Price (A):	 	 
	 	 	 
	Market value of Common Stock on date of exercise (B)	 	 
	 	 	 
	Date of Exercise	 	 
	 	 	 
	Basis for determining market price:	 	 
	 	 	 
	Number of Shares to be Issued: N x (B-A)/B	 	 
	 	 	 

 

	 	Very truly yours,

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]